Harvard Bioscience (FRA:HBI0) ROC (Joel Greenblatt) %: -15.19% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HBI0 Harvard Bioscience Inc FRA:HBI0
53 GF Score
Price €4.08
GF Value €6.70
! 9 Warning Signs
View Full Analysis

What is Harvard Bioscience ROC (Joel Greenblatt) %?

Harvard Bioscience FRA:HBI0 53 ROC (Joel Greenblatt) % is -15.19% as of Jun. 2026. GuruFocus rates FRA:HBI0 with a GF Score™ of 53/100 and a GF Value™ of €6.70. The stock has 9 warning signs investors should review. Among 837 Medical Devices & Instruments companies, Harvard Bioscience ranks worse than 62.96% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Harvard Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -15.19%.

The historical rank and industry rank for Harvard Bioscience's ROC (Joel Greenblatt) % or its related term are showing as below:

FRA:HBI0' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -157.71   Med: -7.13   Max: 3.41
Current: -12.28

During the past 13 years, Harvard Bioscience's highest ROC (Joel Greenblatt) % was 3.41%. The lowest was -157.71%. And the median was -7.13%.

FRA:HBI0's ROC (Joel Greenblatt) % is ranked worse than
62.96% of 837 companies
in the Medical Devices & Instruments industry
Industry Median: 5.37 vs FRA:HBI0: -12.28

Harvard Bioscience's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Harvard Bioscience  (FRA:HBI0) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Harvard Bioscience ROC (Joel Greenblatt) % Related Terms


Harvard Bioscience ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Harvard Bioscience's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Bioscience ROC (Joel Greenblatt) % Chart

Harvard Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.53 -16.61 2.80 -23.81 -148.38

Harvard Bioscience Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.10 -2.17 -10.98 -20.91 -15.19

FRA:HBI0 vs RVP, MLSS, ZJYL: ROC (Joel Greenblatt) % Comparison

For the Medical Instruments & Supplies subindustry, Harvard Bioscience's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Bioscience ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Harvard Bioscience's ROC (Joel Greenblatt) % falls into.


FRA:HBI0
53GF Score
Harvard Bioscience Inc FRA:HBI0
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harvard Bioscience ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(12.605 + 19.207 + 3.117) - (4.573 + 3.171 + 11.555)
=15.63

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(12.586 + 19.296 + 2.803) - (5.402 + 3.126 + 11.605)
=14.552

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Harvard Bioscience for the quarter that ended in Jun. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-3.828/( ( (10.033 + max(15.63, 0)) + (10.196 + max(14.552, 0)) )/ 2 )
=-3.828/( ( 25.663 + 24.748 )/ 2 )
=-3.828/25.2055
=-15.19 %

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -15.19% mean?
Harvard Bioscience (FRA:HBI0) has a ROC (Joel Greenblatt) % of -15.19% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Harvard Bioscience and its competitors. According to the industry distribution chart, Harvard Bioscience ranks #527 out of 837 companies in the Medical Devices & Instruments industry, placing it in the top 63%.
Is Harvard Bioscience's ROC (Joel Greenblatt) % too high?
Harvard Bioscience's current ROC (Joel Greenblatt) % is -15.19%. Based on the distribution chart, Harvard Bioscience ranks #527 out of 837 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Harvard Bioscience has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's ROC (Joel Greenblatt) % compare to RVP and MLSS?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #527 out of 837 companies for ROC (Joel Greenblatt) %. This places Harvard Bioscience in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 5.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 5.37, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Harvard Bioscience and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 5.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Bioscience's current ROC (Joel Greenblatt) % is -15.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current ROC (Joel Greenblatt) % of -15.19%. The stock's GF Value™ is €6.70, compared to a current price of €4.08 — trading 39.1% below its estimated fair value. The current ROC (Joel Greenblatt) % is -15.19%. Harvard Bioscience's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current ROC (Joel Greenblatt) % is -15.19% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued. The current stock price of €4.08 is trading 39.1% below its estimated GF Value™ of €6.70.

Key valuation signals for FRA:HBI0:

  • ROC (Joel Greenblatt) %: -15.19%
  • GF Value™: €6.70 vs. price of €4.08 (39.1% below fair value)
  • GF Score™: 53/100 with 9 warning signs

No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Harvard Bioscience Business Description

Other Exchanges HBIO:USA
Address 84 October Hill Road, Suite 10, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
53GF Score

Get the complete analysis for FRA:HBI0

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price
€6.70
GF Value